Area:
Neurodegenerative diseases, HDACs, Parkinson's Disease
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Farah H. Bardai is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2014 — 2016 |
Bardai, Farah H |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Lrrk Interacts With Tau Through the Actin Cytoskeleton @ Brigham and Women's Hospital
DESCRIPTION (provided by applicant): Mutations in LRRK2 are the most common cause of autosomal dominant Parkinson's disease (PD), and predispose to sporadic PD as well. Some patients with LRRK2 mutations and PD manifest neuropathologically as tauopathies, with deposition of abnormally aggregated tau in affected brain regions. We have been thus motivated to explore the interaction of LRRK and tau using our Drosophila model of tauopathy. We find that either decreasing or increasing levels of the fly homolog of LRRK2, Lrrk, enhances tau neurotoxicity. In our proposed studies we will now test the specific hypothesis that Lrrk enhances tau neurotoxicity by abnormally stabilizing actin. We further posit that increased levels of F-actin then promote mislocalization of the critical mitochondrial fission protein Drp1 and result in mitochondrial morphological changes and increased oxidative stress, as we have previously demonstrated in our tauopathy model. We also propose, based on our preliminary data, that LRRK2- associated neurodegeneration reflects loss of LRRK function, through a dominant negative effect in the case of dominant human mutations. We will also test this hypothesis in our Drosophila model. In a final series of experiments to validate our hypotheses, we will examine F-actin levels, Drp1 localization and mitochondrial pathology in mice expressing human tau in the context of wild type or mutant human LRRK2. All together these experiments are expected to define an important functional role for LRRK2 in controlling the actin cytoskeleton and to define the mechanism of PD-related LRRK2 mutations. In concert with these important scientific goals, the research plan will provide strong training in genetics, cell biology and neuropathology for the fellowship candidate, Dr. Farah Bardai.
|
0.988 |